Last reviewed · How we verify
Propoxyphene Compound 65 (dextropropoxyphene)
Dextropropoxyphene (Propoxyphene Compound 65) is a marketed opioid analgesic used for pain management, with a key composition patent expiring in 2028. Its primary competitive advantage lies in its mechanism of action, which effectively binds to opioid receptors to provide pain relief. However, the primary risk is the strong competition from off-patent drugs like methadone, which has 13 generics available in the market.
At a glance
| Generic name | dextropropoxyphene |
|---|---|
| Drug class | Opioid Agonist |
| Target | Mu-type opioid receptor |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
- Pain
Common side effects
Drug interactions
- rasagiline
- ritonavir
- selegiline
- sodium oxybate
- tranylcypromine
Key clinical trials
- Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions (PHASE2,PHASE3)
- Lumbar Stenosis Outcomes Research II (PHASE4)
- Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain (PHASE4)
- Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propoxyphene Compound 65 CI brief — competitive landscape report
- Propoxyphene Compound 65 updates RSS · CI watch RSS
- portfolio CI